Pharmaceutical Executive
Pharmaceutical Executive: May 2026
Volume: 46
Issue: 4
Pharmaceutical Executive: April 2026
Volume: 46
Issue: 3
Pharmaceutical Executive: March 2026
Volume: 46
Issue: 2
Pharmaceutical Executive: February 2026
Volume: 46
Issue: 1
Pharmaceutical Executive: December 2025
Volume: 45
Issue: 9
Pharmaceutical Executive: October 2025
Volume: 45
Issue: 8
Pharmaceutical Executive: September 2025
Volume: 45
Issue: 7
Pharmaceutical Executive: August 2025
Volume: 45
Issue: 6
Pharmaceutical Executive: June 2025
Volume: 45
Issue: 5
Pharmaceutical Executive: May 2025
Volume: 45
Issue: 4
Pharmaceutical Executive: April 2025
Volume: 45
Issue: 3
Pharmaceutical Executive: March 2025
Volume: 45
Issue: 2
Pharmaceutical Executive: February 2025
Volume: 45
Issue: 1
Pharmaceutical Executive: December 2024
Volume: 44
Issue: 12
Pharmaceutical Executive: November 2024
Volume: 44
Issue: 11
Pharmaceutical Executive: October 2024
Volume: 44
Issue: 10
Pharmaceutical Executive: September 2024
Volume: 44
Issue: 9
Pharmaceutical Executive: July/August 2024
Volume: 44
Issue: 7/8
Pharmaceutical Executive: June 2024
Volume: 44
Issue: 6
Pharmaceutical Executive: May 2024
Volume: 44
Issue: 5
Pharmaceutical Executive: April 2024
Volume: 44
Issue: 4
Pharmaceutical Executive: March 2024
Volume: 44
Issue: 3
Pharmaceutical Executive: February 2024
Volume: 44
Issue: 1
Pharmaceutical Executive: December 2023
Volume: 43
Issue: 12
Pharmaceutical Executive: November 2023
Volume: 43
Issue: 11
Pharmaceutical Executive: October 2023
Volume: 43
Issue: 10
Pharmaceutical Executive: September 2023
Volume: 43
Issue: 9
Pharmaceutical Executive: August 2023
Volume: 43
Issue: 8
Pharmaceutical Executive: July 2023
Volume: 43
Issue: 7
Pharmaceutical Executive: June 2023
Volume: 43
Issue: 6
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly to Deny 340B Drug Pricing Due to Claims-Data Policy: Report
2
What’s Trending in Oncology? A Discussion Following ASCO 2026 with Anne Marie Robertson from EVERSANA
3
New FDA Draft Guidance Targets Gene Therapy Submission Burden by Allowing Use of Existing CMC and Scientific Knowledge
4
Ascidian and Eli Lilly Enter $1.9 Billion Global Research Collaboration to Develop RNA Exon Editors
5